SBTX
Silverback Therapeutics, Inc.
1W: -4.5%
1M: +16.5%
3M: +16.7%
1Y: -33.3%
$5.87
Last traded 2022-11-08 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$550.4M
52W Range2.8-7.545
Volume116,690
Avg Volume172,780
Beta0.00
Dividend—
Analyst Ratings
Company Info
CEOPeter A. Thompson
Employees90
SectorHealthcare
IndustryBiotechnology
IPO Date2020-12-03
Websitesilverbacktx.com
500 Fairview Avenue North
Seattle, WA 98109
US
Seattle, WA 98109
US
206 456 2900
About Silverback Therapeutics, Inc.
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lowenthal Richard E | A-Award | 880,000 | $5.58 | 2024-01-02 |
| Lowenthal Richard E | A-Award | 300,000 | $5.58 | 2024-01-02 |
| Karas Eric | A-Award | 200,000 | $5.58 | 2024-01-02 |
| Tanimoto Sarina | A-Award | 880,000 | $5.58 | 2024-01-02 |
| Tanimoto Sarina | A-Award | 300,000 | $5.58 | 2024-01-02 |